Načítá se...

ET-19 A PHASE 1 STUDY EVALUATING ABT-414 WITH TEMOZOLOMIDE (TMZ) OR CONCURRENT RADIOTHERAPY (RT) AND TMZ IN GLIOBLASTOMA (GBM)

BACKGROUND: Standard therapies have little effect on the poor survival rates of GBM. Abnormal epidermal growth factor receptor (EGFR) expression and signaling are common in GBM. ABT-414 is a unique antibody-drug conjugate, with a toxic payload (MMAF) targeted to active EGFR or mutant EGFRvIII, that...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gan, Hui K., Fichtel, Lisa, Lassman, Andrew B., Merrell, Ryan, van den Bent, Martin, Kumthekar, Priya, Scott, Andrew M., Pedersen, Michelle, Gomez, Erica, Fischer, JuDee, Ames, William, Xiong, Hao, Dudley, Matt, Munasinghe, Wijith, Roberts-Rapp, Lisa, Ansell, Peter, Holen, Kyle, Reardon, David A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2014
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218114/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou255.19
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!